GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Change In Receivables

RemeGen Co (SHSE:688331) Change In Receivables : ¥-462 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co Change In Receivables?

RemeGen Co's change in receivables for the quarter that ended in Jun. 2024 was ¥-190 Mil. It means RemeGen Co's Accounts Receivable increased by ¥190 Mil from Dec. 2023 to Jun. 2024 .

RemeGen Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-246 Mil. It means RemeGen Co's Accounts Receivable increased by ¥246 Mil from Dec. 2022 to Dec. 2023 .

RemeGen Co's Accounts Receivable for the quarter that ended in Jun. 2024 was ¥308 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. RemeGen Co's Days Sales Outstanding for the six months ended in Jun. 2024 was 75.98.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. RemeGen Co's liquidation value for the six months ended in Jun. 2024 was ¥-1,612 Mil.

RemeGen Co Change In Receivables Historical Data

The historical data trend for RemeGen Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Change In Receivables Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial 20.80 - -39.31 -488.32 -246.47

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -205.52 -282.80 25.45 -271.92 -190.10

RemeGen Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ¥-462 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co  (SHSE:688331) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

RemeGen Co's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=307.924/739.656*91
=75.98

2. In Ben Graham's calculation of liquidation value, RemeGen Co's accounts receivable are only considered to be worth 75% of book value:

RemeGen Co's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=877.017-3089.927+0.75 * 307.924+0.5 * 740.65
=-1,612

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Change In Receivables
Comparable Companies
HKSE:09926 HKSE:01877 HKSE:06990 HKSE:01548 HKSE:01530 HKSE:02162 HKSE:06826 HKSE:09969 HKSE:01541 HKSE:09966 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
REGMF:USA 09995:Hong Kong REG:Germany
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
Website
https://www.remegen.com
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

No Headlines